BR9709845B1 - preparaÇço aquosa de insulina, formulaÇço farmacÊutica parenteral, e, processso para aumentar a estabilidade quÍmica de uma preparaÇço de insulina. - Google Patents

preparaÇço aquosa de insulina, formulaÇço farmacÊutica parenteral, e, processso para aumentar a estabilidade quÍmica de uma preparaÇço de insulina.

Info

Publication number: BR9709845B1
Authority: BR; Brazil
Prior art keywords: insulin preparation; chemical stability; enhancing; pharmaceutical formulation; parenteral pharmaceutical
Prior art date: 1996-06-20

Application number

BRPI9709845-0A

Other languages

English (en)

Other versions

BR9709845A (pt

Inventor

Elsebeth Norup

Liselotte Langkjaer

Svend Havelund

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-06-20

Filing date

1997-06-19

Publication date

2008-11-18

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8096378&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR9709845(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1997-06-19 Application filed filed Critical

1999-08-10 Publication of BR9709845A publication Critical patent/BR9709845A/pt

2008-11-18 Publication of BR9709845B1 publication Critical patent/BR9709845B1/pt

Links

NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 title abstract 6
102000004877 Insulin Human genes 0.000 title abstract 3
108090001061 Insulin Proteins 0.000 title abstract 3
229940125396 insulin Drugs 0.000 title abstract 3
238000002360 preparation method Methods 0.000 title abstract 3
239000000126 substance Substances 0.000 title abstract 2
230000002708 enhancing effect Effects 0.000 title 1
238000000034 method Methods 0.000 title 1
239000008194 pharmaceutical composition Substances 0.000 title 1
PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 abstract 3
FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 1
101000976075 Homo sapiens Insulin Proteins 0.000 abstract 1
229930195725 Mannitol Natural products 0.000 abstract 1
PBGKTOXHQIOBKM-FHFVDXKLSA-N insulin (human) Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@H]1CSSC[C@H]2C(=O)N[C@H](C(=O)N[C@@H](CO)C(=O)N[C@H](C(=O)N[C@H](C(N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=3C=CC(O)=CC=3)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3C=CC(O)=CC=3)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC=3NC=NC=3)NC(=O)[C@H](CO)NC(=O)CNC1=O)C(=O)NCC(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)NCC(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H]([C@@H](C)O)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)O)C(O)=O)C(=O)N[C@@H](CC(N)=O)C(O)=O)=O)CSSC[C@@H](C(N2)=O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C(C)C)NC(=O)[C@@H](NC(=O)CN)[C@@H](C)CC)[C@@H](C)CC)[C@@H](C)O)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@@H](NC(=O)[C@@H](N)CC=1C=CC=CC=1)C(C)C)C1=CN=CN1 PBGKTOXHQIOBKM-FHFVDXKLSA-N 0.000 abstract 1
239000000594 mannitol Substances 0.000 abstract 1
235000010355 mannitol Nutrition 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/28—Insulins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Oil, Petroleum & Natural Gas (AREA)
Zoology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Immunology (AREA)
Gastroenterology & Hepatology (AREA)
Hematology (AREA)
Inorganic Chemistry (AREA)
Obesity (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Biochemistry (AREA)
Molecular Biology (AREA)
Emergency Medicine (AREA)
Dermatology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicinal Preparation (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

BRPI9709845-0A 1996-06-20 1997-06-19 preparaÇço aquosa de insulina, formulaÇço farmacÊutica parenteral, e, processso para aumentar a estabilidade quÍmica de uma preparaÇço de insulina. BR9709845B1 (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
DK68596		1996-06-20
PCT/DK1997/000268 WO1997048414A1 (en)	1996-06-20	1997-06-19	INSULIN PREPARATIONS CONTAINING NaCl

Publications (2)

Publication Number	Publication Date
BR9709845A BR9709845A (pt)	1999-08-10
BR9709845B1 true BR9709845B1 (pt)	2008-11-18

Family

ID=8096378

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BRPI9709845-0A BR9709845B1 (pt)	1996-06-20	1997-06-19	preparaÇço aquosa de insulina, formulaÇço farmacÊutica parenteral, e, processso para aumentar a estabilidade quÍmica de uma preparaÇço de insulina.

Country Status (21)

Country	Link
EP (1)	EP0921812B2 (pt)
JP (2)	JP4404380B2 (pt)
KR (1)	KR100451778B1 (pt)
CN (1)	CN1120019C (pt)
AT (1)	ATE208208T1 (pt)
AU (1)	AU720484B2 (pt)
BR (1)	BR9709845B1 (pt)
CA (1)	CA2258097C (pt)
CZ (1)	CZ297937B6 (pt)
DE (1)	DE69708121T3 (pt)
DK (1)	DK0921812T4 (pt)
ES (1)	ES2167751T5 (pt)
HU (1)	HU228094B1 (pt)
IL (2)	IL127366A0 (pt)
NO (1)	NO324430B1 (pt)
PL (1)	PL189964B1 (pt)
PT (1)	PT921812E (pt)
RU (1)	RU2182015C2 (pt)
UA (1)	UA49890C2 (pt)
WO (1)	WO1997048414A1 (pt)
ZA (1)	ZA975470B (pt)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
AU1870099A (en) *	1998-01-09	1999-07-26	Novo Nordisk A/S	Stabilised insulin compositions
EP1131089B1 (en) *	1998-11-18	2004-02-18	Novo Nordisk A/S	Stable aqueous insulin preparations without phenol and cresol
US6489292B1 (en)	1998-11-18	2002-12-03	Novo Nordisk A/S	Stable aqueous insulin preparations without phenol and cresol
AU2624400A (en) *	1999-01-26	2000-08-07	Eli Lilly And Company	Monodisperse hexameric acylated insulin analog formulations
CA2362116A1 (en) *	1999-04-05	2000-10-12	Igor Anatolievich Pomytkin	Use of succinic acid or salts thereof for the treatment of diabetes mellitus and wound healing
EP1523993A1 (en) *	1999-12-16	2005-04-20	Eli Lilly & Company	Polypeptide compositions with improved stability
EA004631B1 (ru) *	1999-12-16	2004-06-24	Эли Лилли Энд Компани	Полипептидные композиции, обладающие повышенной стабильностью
US7022674B2 (en)	1999-12-16	2006-04-04	Eli Lilly And Company	Polypeptide compositions with improved stability
CA2581798A1 (en)	2004-10-05	2006-04-13	Petter Lybeck	A pharmaceutical formulation comprising crystalline insulin and dissolved insulin
RU2288000C1 (ru) *	2005-04-27	2006-11-27	Институт нефтехимического синтеза им. А.В. Топчиева РАН (ИНХС РАН)	Раствор инсулина для перорального введения
EP3677275B1 (de)	2008-10-17	2024-06-12	Sanofi-Aventis Deutschland GmbH	Kombination von einem insulin und einem glp-1-agonisten
ES2965209T3 (es)	2009-11-13	2024-04-11	Sanofi Aventis Deutschland	Composición farmacéutica que comprende desPro36exendina-4(1-39)-Lys6-NH2 y metionina
PL2498802T3 (pl)	2009-11-13	2015-06-30	Sanofi Aventis Deutschland	Kompozycja farmaceutyczna zawierająca agonistę GLP-1, insulinę i metioninę
JP6199186B2 (ja)	2010-08-30	2017-09-20	サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング	２型糖尿病の治療用の医薬の製造のためのａｖｅ００１０の使用
US9821032B2 (en)	2011-05-13	2017-11-21	Sanofi-Aventis Deutschland Gmbh	Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
TWI608847B (zh)	2011-08-29	2017-12-21	賽諾菲阿凡提斯德意志有限公司	用於控制糖尿病二型病患血糖的醫藥組合物
AR087744A1 (es)	2011-09-01	2014-04-16	Sanofi Aventis Deutschland	Composicion farmaceutica para uso en el tratamiento de una enfermedad neurodegenerativa
JP2016505601A (ja) *	2012-12-26	2016-02-25	ウォックハートリミテッド	医薬組成物
TWI780236B (zh)	2013-02-04	2022-10-11	法商賽諾菲公司	胰島素類似物及/或胰島素衍生物之穩定化醫藥調配物
AU2015205624A1 (en)	2014-01-09	2016-07-14	Sanofi	Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
JP2020114861A (ja) *	2014-01-09	2020-07-30	サノフイＳａｎｏｆｉ	インスリンアナログおよび／またはインスリン誘導体の、グリセリンを含まない安定化された医薬製剤
CN105899191B (zh)	2014-01-09	2020-06-16	赛诺菲	胰岛素类似物和/或胰岛素衍生物的稳定化不含甘油的药物制剂
JP2020143105A (ja) *	2014-01-09	2020-09-10	サノフイＳａｎｏｆｉ	インスリンアスパルトの安定化された医薬製剤
EP3091964A1 (en) *	2014-01-09	2016-11-16	Sanofi	Stabilized pharmaceutical formulations of insulin aspart
ES2949095T3 (es)	2014-12-12	2023-09-25	Sanofi Aventis Deutschland	Formulación de relación fija de insulina glargina/lixisenatida
TWI748945B (zh)	2015-03-13	2021-12-11	德商賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患治療
TW201705975A (zh)	2015-03-18	2017-02-16	賽諾菲阿凡提斯德意志有限公司	第２型糖尿病病患之治療
JP2023549542A (ja) *	2020-11-16	2023-11-27	ダブリュ．エル．ゴアアンドアソシエイツ，インコーポレイティド	曇点の無い製剤、方法及び予充填複数回投与注入機器

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DK116527B (da) *	1967-03-01	1970-01-19	Nordisk Insulinlab	Fremgangsmåde til fremstilling af en hurtigtvirkende, holdbar, neutral opløsning af rent krystallinsk okseinsulin eller okseinsulin, der ved tilsætning af Zn er krystalliserbart i vand, eller blandinger af okseinsulin og insulin af anden oprindelse.
SU1528496A1 (ru) *	1972-10-17	1989-12-15	Днепропетровский Научно-Исследовательский Институт Гастроэнтерологии	Дегидратирующее средство
US4783441A (en) †	1979-04-30	1988-11-08	Hoechst Aktiengesellschaft	Aqueous protein solutions stable to denaturation
US4439181A (en) *	1981-01-26	1984-03-27	Regents Of The University Of Minnesota	Polyol-hormone mixture for use in chronic parenteral hormone administration
AU550068B2 (en) †	1981-03-10	1986-02-27	Novo Nordisk A/S	Zinc insulin stabilized with calcium or magnesium salts
US4839341A (en) *	1984-05-29	1989-06-13	Eli Lilly And Company	Stabilized insulin formulations
PH25772A (en) *	1985-08-30	1991-10-18	Novo Industri As	Insulin analogues, process for their preparation
IL93282A (en) *	1989-02-09	1995-08-31	Lilly Co Eli	Insulin analogues
DK0705275T3 (da) *	1993-06-21	1999-09-20	Novo Nordisk As	AspB28-insulin-krystaller
CA2171424C (en) *	1993-09-17	2002-06-04	Svend Havelund	Acylated insulin
US5474978A (en) *	1994-06-16	1995-12-12	Eli Lilly And Company	Insulin analog formulations
US5461031A (en) *	1994-06-16	1995-10-24	Eli Lilly And Company	Monomeric insulin analog formulations

1997
- 1997-06-19 BR BRPI9709845-0A patent/BR9709845B1/pt not_active IP Right Cessation
- 1997-06-19 CN CN97195648A patent/CN1120019C/zh not_active Expired - Lifetime
- 1997-06-19 PT PT97928123T patent/PT921812E/pt unknown
- 1997-06-19 WO PCT/DK1997/000268 patent/WO1997048414A1/en not_active Ceased
- 1997-06-19 PL PL97330763A patent/PL189964B1/pl unknown
- 1997-06-19 DK DK97928123.5T patent/DK0921812T4/da active
- 1997-06-19 DE DE69708121T patent/DE69708121T3/de not_active Expired - Lifetime
- 1997-06-19 CZ CZ0395698A patent/CZ297937B6/cs not_active IP Right Cessation
- 1997-06-19 CA CA2258097A patent/CA2258097C/en not_active Expired - Lifetime
- 1997-06-19 RU RU99101068/14A patent/RU2182015C2/ru active
- 1997-06-19 EP EP97928123A patent/EP0921812B2/en not_active Expired - Lifetime
- 1997-06-19 AU AU32536/97A patent/AU720484B2/en not_active Expired
- 1997-06-19 UA UA98126686A patent/UA49890C2/uk unknown
- 1997-06-19 AT AT97928123T patent/ATE208208T1/de active
- 1997-06-19 ES ES97928123T patent/ES2167751T5/es not_active Expired - Lifetime
- 1997-06-19 IL IL12736697A patent/IL127366A0/xx active IP Right Grant
- 1997-06-19 JP JP50212998A patent/JP4404380B2/ja not_active Expired - Lifetime
- 1997-06-19 HU HU9904031A patent/HU228094B1/hu unknown
- 1997-06-19 KR KR10-1998-0710429A patent/KR100451778B1/ko not_active Expired - Lifetime
- 1997-06-20 ZA ZA9705470A patent/ZA975470B/xx unknown
1998
- 1998-12-02 IL IL127366A patent/IL127366A/en not_active IP Right Cessation
- 1998-12-18 NO NO19985981A patent/NO324430B1/no not_active IP Right Cessation
2009
- 2009-05-07 JP JP2009112970A patent/JP2009235075A/ja not_active Withdrawn

Also Published As

Publication number	Publication date
EP0921812A1 (en)	1999-06-16
HUP9904031A2 (hu)	2000-04-28
DK0921812T3 (da)	2002-02-11
JP2009235075A (ja)	2009-10-15
NO985981L (no)	1998-12-18
RU2182015C2 (ru)	2002-05-10
KR20000022031A (ko)	2000-04-25
CZ395698A3 (cs)	1999-05-12
ES2167751T3 (es)	2002-05-16
IL127366A (en)	2007-07-04
ZA975470B (en)	1997-12-22
BR9709845A (pt)	1999-08-10
UA49890C2 (uk)	2002-10-15
IL127366A0 (en)	1999-10-28
PL189964B1 (pl)	2005-10-31
ES2167751T5 (es)	2012-03-30
ATE208208T1 (de)	2001-11-15
AU3253697A (en)	1998-01-07
JP4404380B2 (ja)	2010-01-27
KR100451778B1 (ko)	2004-11-16
DE69708121T3 (de)	2012-05-16
CN1222083A (zh)	1999-07-07
PT921812E (pt)	2002-04-29
CA2258097C (en)	2011-02-08
HU228094B1 (en)	2012-10-29
AU720484B2 (en)	2000-06-01
WO1997048414A1 (en)	1997-12-24
DE69708121T2 (de)	2002-08-01
CA2258097A1 (en)	1997-12-24
NO324430B1 (no)	2007-10-15
DE69708121D1 (de)	2001-12-13
EP0921812B1 (en)	2001-11-07
CZ297937B6 (cs)	2007-05-02
HUP9904031A3 (en)	2000-10-30
EP0921812B2 (en)	2011-12-21
DK0921812T4 (da)	2012-04-02
PL330763A1 (en)	1999-05-24
NO985981D0 (no)	1998-12-18
CN1120019C (zh)	2003-09-03
JP2000513344A (ja)	2000-10-10

Publication	Publication Date	Title
BR9709845B1 (pt)	2008-11-18	preparaÇço aquosa de insulina, formulaÇço farmacÊutica parenteral, e, processso para aumentar a estabilidade quÍmica de uma preparaÇço de insulina.
BR9709844A (pt)	1999-08-10	Preparação aquosa de insulina formulação farmacêutica parenteral usos de um carboidrato n o-redutor ou reduzido e de manitol sorbitol xilitol inositol trealose sacarose ou qualquer sua mistura e processo de fabricação de uma preparação de insulina
YU59192A (sh)	1994-12-28	Formulacija aerosola koje ne sadrže hlorofluorougljenična jedinjenja
ES2179040T3 (es)	2003-01-16	Utilizacion de 5-fluoro-2'-desoxi-3'-tiacitidina para el tratamiento de la hepatitis b.
PT1121144E (pt)	2002-11-29	Preparados de insulina concentrada estavel para administracao pulmonar
DK395689A (da)	1990-02-14	Pharmaceutisk tilberedning til behandling af diabetes mellitus
NO903941D0 (no)	1990-09-10	Analogifremgangsmaate for fremstilling av terapeutisk aktive diazepinon-derivater.
EE200000226A (et)	2001-06-15	3,6-poolketaalid 9a-asaliidide klassist, nende valmistamismeetod ja farmatseutiline kompositsioon
NO902710D0 (no)	1990-06-19	Analogifremgangsmaate for fremstilling av terapeutisk aktive r(-) 3-kinuklidinol-derivater.
GR1001511B (el)	1994-02-28	Στεροειδείς συν?έσεις.
MX9704034A (es)	1998-02-28	Derivados y composiciones de 1,1-dioxido de 2-arilcarboniloximetil-1,2,5-tiadiazolidin-3-ona substituido y metodo de uso.
IS1910B (is)	2003-12-31	Notkun á fankínóni til meðhöndlunar á Alzheimers-sjúkdómi
IT1229491B (it)	1991-09-03	Derivati della 1,2,5,6-tetraidropiridina, loro procedimento di preparazione e loro impiego come sostanze medicinali
IT1227436B (it)	1991-04-11	Derivati di 1-azabicicloalcani, loro procedimento di preparazione e loro applicazione come farmaci
ATE196914T1 (de)	2000-10-15	Lh-rh analoge mit starrer konformation, deren verwendungen und pharmazeutische zusammensetzungen
IT1233446B (it)	1992-04-01	Derivati della 3 piperidinocarbaldeide ossima, loro procedimento di preparazione e loro applicazione come farmaci
ES2060440T3 (es)	1994-11-16	Derivados de acidos 1,4-dihidropiridin-dicarboxilicos aril-quinolil substituidos, procedimiento para su fabricacion y su uso en medicamentos.
ATE106732T1 (de)	1994-06-15	Arzneimittelzubereitung, enthaltend stigmasta-4- en-3-on sowie deren verwendung.
BR9813102A (pt)	2000-08-22	Derivados de ácido metilenobisfosfÈnico novos
IT1237783B (it)	1993-06-17	Derivati di ferro-albumina biodisponibile, loro procedimento di preparazione e relative composizioni farmaceutiche.
BR9813037A (pt)	2000-08-15	Composto, processo para sua preparação, uso do mesmo, preparação farmacêutica, e, combinação desta com pelo menos uma outra substância ativa
FI870787A7 (fi)	1987-08-25	Puhdistettu ihmisen angiogeeninen tekijä, menetelmä sen valmistamiseksi ja farmaseuttisia koostumuksia.
IT8720271A0 (it)	1987-04-24	Nuovi derivati dell'ergolene, composizioni farmaceutiche che licontengono e procedimento per lapreparazione dei medesimi.
IT8620737A0 (it)	1986-06-10	Composizioni farmaceutiche contenenti levodopa metil estere, loro procedimento di preparazione e relative applicazioni terapeutiche.
IT8719221A0 (it)	1987-01-30	Composizioni farmaceutiche contenenti levodopa metil estere, loro prodecimento di preparazione e relative applicazioni terapeutiche.

Legal Events

Date	Code	Title	Description
2004-05-25	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2004-12-21	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2005-08-23	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2006-03-14	B06A	Patent application procedure suspended [chapter 6.1 patent gazette]
2008-04-15	B09A	Decision: intention to grant [chapter 9.1 patent gazette]
2008-12-02	B16A	Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]	Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 02/12/2008, OBSERVADAS AS CONDICOES LEGAIS.
2019-02-05	B21A	Patent or certificate of addition expired [chapter 21.1 patent gazette]	Free format text: PATENTE EXTINTA EM 02.12.2018